Published in

American Heart Association, Stroke, 9(45), p. 2662-2669, 2014

DOI: 10.1161/strokeaha.114.005990

Links

Tools

Export citation

Search in Google Scholar

Fibrinolysis for Intraventricular Hemorrhage

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Background and Purpose— Intraventricular hemorrhage is associated with high mortality and poor functional outcome. The use of intraventricular fibrinolytic (IVF) therapy as an intervention in intraventricular hemorrhage is an evolving therapy with conflicting reports in the literature. The goal of this study is to investigate the impact of IVF on mortality, functional outcome, ventriculitis, shunt dependence, and rehemorrhage. Methods— During March and April 2014, a systematic literature search was performed identifying 1359 articles. Of these, 24 met inclusion criteria. A random effects meta-analysis was performed using both pooled and subset analysis based on study type. Results— Our meta-analysis demonstrated that IVF reduced mortality in intraventricular hemorrhage by nearly half (relative risk [RR], 0.55; 95% confidence interval [CI], 0.42–0.71; P <0.00001), increased the likelihood of good functional outcome by 66% (RR, 1.66; 95% CI, 1.27–2.19; P =0.0003), and also decreased the rate of shunt dependence (RR, 0.62; 95% CI, 0.42–0.93; P =0.02). IVF was not found to be associated with increased rates of ventriculitis (RR=1.46; 95% CI, 0.77–2.76; P =0.25) or rehemorrhage (RR=1.06; 95% CI, 0.66–1.70; P =0.80). We detected no evidence of publication bias. Conclusions— Our meta-analysis showed that IVF is safe and could be an effective strategy for the treatment of intraventricular hemorrhage. It may reduce mortality, improve functional outcome, and diminish the need for permanent ventricular shunting, while not increasing the risk of ventriculitis or rehemorrhage.